Sertraline Treatment of Posttraumatic Stress Disorder: Results of 24 Weeks of Open-Label Continuation Treatment
J Clin Psychiatry 2001;62:325-331
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Posttraumatic stress disorder
(PTSD) is typically associated with a high degree of chronicity,
comorbidity, and psychosocial disability. The efficacy of
sertraline in the acute treatment of PTSD has been confirmed
based on the results of 2 large, placebo-controlled studies, but
almost no prospective long-term treatment studies have been
Method: One hundred twenty-eight patients
who completed 12 weeks of double-blind, placebo-controlled,
acute-phase treatment for DSM-III-R-defined PTSD with sertraline
were continued into a 24-week open-label continuation phase.
Efficacy was evaluated using the endpoint change in the 17-item
Clinician Administered PTSD Scale Part 2 (CAPS-2) severity score,
the 15-item patient-rated Impact of Event Scale, and the Clinical
Global Impressions-Improvement and -Severity of Illness scales as
primary outcome measures. Treatment response was defined as >=
30% decrease in the CAPS-2 total severity score (compared with
acute-phase baseline score) and a Clinical Global
Impressions-Improvement score of 1 or 2.
Results: Ninety-two percent of acute-phase
responders maintained their response during the full 6 months of
continuation treatment. In addition, 54% of acute-phase
nonresponders converted to responder status during continuation
therapy. Over the 36-week course of acute and continuation
therapy, 20% to 25% of the improvement in the CAPS-2 severity
score occurred during the continuation phase. Sertraline was well
tolerated, with 8.6% of patients discontinuing due to adverse
events. A high pretreatment CAPS-2 score (> 75) predicted a
longer time to response and a greater likelihood that response
occurred after 12 weeks of acute treatment.
Conclusion: The acute efficacy of sertraline is
sustained in the vast majority of patients, and at least half of
nonresponders to acute treatment will eventually respond to